Core Viewpoint - Rani Therapeutics has announced a private placement of Class A common stock and accompanying warrants, expected to generate approximately $60.3 million in gross proceeds, aimed at funding operations into 2028 and advancing its RaniPill® platform [1][3][4] Private Placement Details - The private placement will involve the issuance of 42,633,337 shares of Class A common stock at a price of $0.48 per share and pre-funded warrants at $0.4799 per warrant, with an exercise price of $0.0001 per share for the pre-funded warrants [5] - The accompanying warrants will allow the purchase of up to 125,000,004 shares of Class A common stock at an exercise price of $0.48 per share, exercisable upon stockholder approval [5][6] Use of Proceeds - Net proceeds from the private placement, along with an upfront payment of $10 million and an expected $18 million technology transfer milestone from Chugai Pharmaceuticals, will support the company's operations and pipeline development through 2028 [3][4] Strategic Partnerships - The financing is seen as a pivotal moment for Rani, combining its oral delivery technology with Chugai's expertise in antibody development, aiming to create transformative oral therapies for rare diseases [4][12] Investor Participation - The private placement was led by Samsara BioCapital, with participation from other investors including RA Capital Management and Anomaly, and includes a provision for Samsara and Anomaly to designate board members [6][7][8] Debt Conversion - Avenue Venture Opportunities Fund will convert $6 million of outstanding debt into 12,500,000 shares of Class A common stock and receive warrants on the same terms as other investors, reducing the company's debt obligations [9]

Group 1 - Rani Therapeutics has entered into a securities purchase agreement for the sale of 4,354,000 shares of Class A common stock at $0.40 per share and pre-funded warrants for 3,146,000 shares at $0.3999 per share [1][2] - The offering is expected to close on or about July 16, 2025, with gross proceeds estimated at approximately $3.0 million before deducting fees and expenses [2] - The securities are being offered under a "shelf" registration statement declared effective by the SEC on August 10, 2022, and a final prospectus supplement will be filed with the SEC [3] Group 2 - Rani Therapeutics is a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and drugs, including the RaniPill® capsule [4] - The RaniPill® capsule is designed to replace subcutaneous injections or intravenous infusions with oral dosing, and the company has conducted several studies to evaluate its safety and bioavailability [4]

Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Receptor Agonist (PG-102) via a Robotic Pill (RT- 114) Achieves Bioequivalence to Subcutaneous Injection in Canines Session Type: Poster Presentation Session Title: Adipose Tissue, Appetite, and Obesity: From Breakthroughs to Real-World Challenges: Navigating Weight Loss, Regain, and Therapeutic Advances II Session Date & Time: July 14, 2025 from 12:00 PM to 1:30 PM PT Poster Number: MON-691 SAN JOSE, Cali ...

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) taking place July 12-15 in San Francisco, CA. Details of the presentations are as follows: Abstract Title: Oral Delivery of a Bispecific GLP-1/GLP-2 Rec ...

Core Insights - Rani Therapeutics announced promising preclinical data for RT-114, a bispecific GLP-1/GLP-2 receptor agonist, demonstrating bioequivalence to subcutaneous administration when delivered orally via the RaniPill® capsule [1][7] - The company plans to initiate a Phase 1 clinical trial for RT-114 targeting obesity in mid-2025 [4] - Financial results for Q1 2025 show a net loss of $12.7 million, an improvement from a net loss of $14.8 million in Q1 2024 [5][13] Preclinical Developments - Preclinical studies indicated that RT-114 achieved a relative bioavailability of 111% compared to subcutaneously administered PG-102, with similar pharmacokinetic profiles [7] - Successful oral delivery of semaglutide via the RaniPill® capsule was also reported, showing comparable bioavailability and weight loss to subcutaneous administration [7] Financial Performance - As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $15.9 million, down from $27.6 million at the end of 2024 [7] - Contract revenue for Q1 2025 was $0.2 million, a new revenue stream compared to no contract revenue in Q1 2024 [7] - Research and development expenses decreased to $6.6 million from $7.6 million in the same period last year, primarily due to lower compensation costs [7] Company Overview - Rani Therapeutics is focused on the oral delivery of biologics and drugs, utilizing the RaniPill® capsule technology to replace traditional subcutaneous injections [8] - The company aims to make oral biologics a reality for patients, particularly those living with obesity [2]